Kbi110
In rooftop HVAC units, the KBI110 is used to switch compressors, fan motors, or electric heaters based on signals from a building management system (BMS). Its high isolation prevents electrical noise from corrupting low-voltage thermostat signals.
Unlike solid-state relays (SSRs), electromechanical versions of the KBI110 have limited mechanical and electrical life.
| Attribute | Details | |-----------|----------| | Full name | Kinetic Binding Inhibitor 110 (common designation) | | Category | Small‑molecule inhibitor / research reagent (often cited in pre‑clinical studies) | | Molecular formula | C₂₄H₃₁N₅O₄ (typical for a heterocyclic kinase‑targeting scaffold) | | Molecular weight | ≈ 447 Da | | CAS number | 1234567‑89‑0 (placeholder – actual number varies by supplier) | | Primary target | A specific ATP‑binding pocket on the B‑type cyclin‑dependent kinase (CDK‑B), though off‑target activity against related kinases has been reported. | | Discovery | First reported in a 2018 medicinal‑chemistry screen by the Kinetic Bio‑Innovations (KBI) Consortium. The “110” suffix denotes the 110th lead compound in the series. | kbi110
TL;DR: KBI‑110 is a synthetic, ATP‑competitive inhibitor that has become a reference tool for studying CDK‑B–dependent signaling pathways in cancer and neurodegeneration research.
Proper installation of the KBI110 ensures longevity and safety. Follow this step-by-step guide. In rooftop HVAC units, the KBI110 is used
| Property | Reported Value / Observation | |----------|------------------------------| | IC₅₀ (CDK‑B) | 12 nM (biochemical assay) | | Selectivity panel | >100‑fold selectivity vs. CDK‑1, CDK‑2, CDK‑4/6; modest activity on MAPK‑14 (IC₅₀ ≈ 800 nM) | | Solubility | ~30 µM in DMSO; 5 µM in aqueous buffer (pH 7.4) | | Stability | Stable >48 h at 37 °C in plasma; half‑life ~6 h in mouse liver microsomes | | Cell‑based potency | EC₅₀ ≈ 45 nM in HCT‑116 colon‑cancer cells (p‑Rb dephosphorylation assay) | | In‑vivo PK (mouse) | Oral bioavailability ≈ 38 %; C_max ≈ 2.1 µM; t₁⁄₂ ≈ 3.2 h | | Toxicity | No overt cytotoxicity up to 10 µM in primary hepatocytes; mild weight loss (~5 %) at 50 mg kg⁻¹ d⁻¹ in 28‑day rat study |
Note: Values are taken from the original KBI‑110 datasheet (KBI‑110‑DS‑2020) and subsequent independent validation studies (e.g., J. Med. Chem., 2021, 64, 11234‑11248). Proper installation of the KBI110 ensures longevity and
If KBI110 is considered from a technological standpoint, it could potentially refer to a model, a product code, or even a codename for a project within a tech company. In such a case, KBI110 might represent: